Mostrar el registro sencillo del ítem

dc.contributor.author
Otero-losada, Matilde Estela  
dc.contributor.author
Petrovsky, Nikolai  
dc.contributor.author
Alami, Abdallah  
dc.contributor.author
Crispo, James  
dc.contributor.author
Mattison, Donald  
dc.contributor.author
Capani, Francisco  
dc.contributor.author
Goetz, Christopher  
dc.contributor.author
Krewski, Daniel  
dc.contributor.author
Perez Lloret, Santiago  
dc.date.available
2024-01-03T14:25:48Z  
dc.date.issued
2022-09  
dc.identifier.citation
Otero-losada, Matilde Estela; Petrovsky, Nikolai; Alami, Abdallah; Crispo, James; Mattison, Donald; et al.; Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom; Taylor & Francis; Expert Opinion On Drug Safety; 22; 4; 9-2022; 343-349  
dc.identifier.issn
1474-0338  
dc.identifier.uri
http://hdl.handle.net/11336/222236  
dc.description.abstract
Background: Information on neurological and psychiatric adverse events following immunization (AEFIs) with COVID-19 vaccines is limited. Research design & methods: We examined and compared neurological and psychiatric AEFIS reports related to BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccines and recorded in the United Kingdom Medicines and Healthcare products Regulatory Agency between 9 December 2020 and 30 June 2021. Results: As of 30 June 2021, 46.1 million doses of ChAdOx1 and 30.3 million doses of BNT162b2 had been administered. The most frequently reported AEFI was headache with 1,686 and 575 cases per million doses of ChAdOx1 and BNT162b2, respectively. AEFIs more frequently reported after CHAdOx1 compared with BNT162b2 vaccination were Guillain-Barré syndrome (OR, 95% CI = 2.53, 1.82–3.51), freezing (6.66, 3.12–14.22), cluster headache (1.53, 1.28–1.84), migraine (1.23,1.17–1.30), postural dizziness (1.24,1.13–1.37), tremor (2.86, 2.68–3.05), headache (1.40, 1.38–1.43), paresthesia (1.11, 1.06–1.16), delirium (1.85, 1.45–2.36), hallucination (2.20, 1.82–2.66), poor quality sleep (1.53, 1.26–1.85), and nervousness (1.54, 1.26–1.89) Reactions less frequently reported with ChAdOx1 than with BNT162b2 were Bell’s palsy (0.47, 0.41–0.55), anosmia (0.58, 0.47–0.71), facial paralysis (0.35, 0.29–0.41), dysgeusia (0.68, 0.62–0.73), presyncope (0.48, 0.42–0.55), syncope (0.63, 0.58–0.67), and anxiety (0.75 (0.67–0.85). Conclusion: Neurological and psychiatric AEFIs were relatively infrequent, but each vaccine was associated with a distinctive toxic profile.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Taylor & Francis  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
BNT162B2  
dc.subject
CHADOX1  
dc.subject
COVID-19  
dc.subject
NEUROLOGY  
dc.subject
PHARMACOVIGILANCE  
dc.subject
PSYCHIATRY  
dc.subject
SAFETY  
dc.subject
VACCINES  
dc.subject.classification
Psiquiatría  
dc.subject.classification
Medicina Clínica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2024-01-02T11:45:45Z  
dc.journal.volume
22  
dc.journal.number
4  
dc.journal.pagination
343-349  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Londres  
dc.description.fil
Fil: Otero-losada, Matilde Estela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Abierta Interamericana. Secretaría de Investigación. Centro de Altos Estudios En Ciencias Humanas y de la Salud - Sede Buenos Aires; Argentina  
dc.description.fil
Fil: Petrovsky, Nikolai. Flinders University.; Australia  
dc.description.fil
Fil: Alami, Abdallah. University of Ottawa; Canadá  
dc.description.fil
Fil: Crispo, James. Carleton University; Canadá. University of British Columbia; Canadá  
dc.description.fil
Fil: Mattison, Donald. University of Ottawa; Canadá. University of South Carolina; Chile  
dc.description.fil
Fil: Capani, Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Abierta Interamericana. Secretaría de Investigación. Centro de Altos Estudios En Ciencias Humanas y de la Salud - Sede Buenos Aires; Argentina. Universidad Autónoma de Chile; Chile  
dc.description.fil
Fil: Goetz, Christopher. Rush University Medical Center (rumc);  
dc.description.fil
Fil: Krewski, Daniel. University of Ottawa; Canadá  
dc.description.fil
Fil: Perez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina  
dc.journal.title
Expert Opinion On Drug Safety  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/14740338.2022.2120607  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1080/14740338.2022.2120607